Six months after it was controversially hailed by Trump administration officials as a "breakthrough" therapy to fight the worst effects of Covid-19, convalescent plasma appears to be on the ropes. The treatment that infuses blood plasma from recovered Covid patients into people newly infected in hopes of boosting their immune response has not lived up
The coronavirus disease 2019 (COVID-19) pandemic – caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – is still causing hundreds of thousands of new cases globally. Therapeutic antibodies have been used to attempt to counter and contain the virus. Convalescent plasma (CP) obtained from recovered COVID-19 patients is also in use in many
Researchers in the United States who tracked the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient found that convalescent plasma therapy was associated with the emergence of viral variants that were less susceptible to neutralizing antibodies. The SARS-CoV-2 virus is the agent responsible for the coronavirus 2019 (COVID-19) pandemic that
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok